Company: BLLN
Filing Date: 2025-06-20
Form Type: DRS
Source: 0000950123-25-006095
Chunk: 163

Company: BillionToOne, Inc.
Filing Date: 2025-06-20
Form: DRS
Chunk 163
---
 molecule sensitivity, absent a complete redesign of not only the assays and bioinformatics, but of the entire laboratory infrastructure. 125

We have also utilized automation and AI throughout our infrastructure to reduce errors and increase laboratory throughput. By automating our labs, we are able to build uniformity into sample processing and can rapidly identify and triage problems as they occur. Each individual lab contains specialized equipment with bespoke programming to drive specific processes and to progress the sample through the testing workflow. In addition, we also integrate third-party large language models and AI to improve our laboratory workflows. For example, we completely redesigned and automated our biological sample accessioning process by incorporating AI and computer vision that automates labor-intensive clerical tasks. This allowed us to redeploy our laboratory personnel to higher impact areas. As a technology-forward organization, we have decreased our COGS by more than % in the 24 months ended June 30, 2025, in part by deploying automation and AI. While our current laboratory space is already sufficient for at least four times more growth, our process engineering and automation teams continue to work on creative solutions to further scale our laboratory capacity and decrease our COGS. IP and know-how Our smNGS platform is protected by a suite of over 40 patents and proprietary technological know-how.Our patented technologies differentiate us from our competitors and support improved quality controls, enable nimble product iteration, and drive rational assay design that allow us to build novel products with attractive gross margins. We have multiple issued patents for our core technologies and our ancillary technology in the United States and internationally. Our core patents cover various approaches to using synthetic molecules to provide accurate counting of target molecules, which is our QCT technology, as well as protecting the following technologies:

| - |     | Dilution tagging is a novel method to quantify the abundance of targeted DNA molecules across a dynamic range of many orders of magnitude. This technology enables low-cost                                 
 sequencing of cfDNA samples with rare sequences without the loss of quantitative information. For example, this can reduce sequencing costs by 10-50x for sequencing intensive applications, such as immune 
 receptor repertoire profiling and single cell RNA sequencing.                                                                                                                                               |

| - |     | Spike-in technology refers to synthetic DNA controls custom-made for each assay and added to every patient sample. These DNA controls enable the calculation of relative 
 abundance of targeted DNA molecules at a low cost.                                                                                                                       |

| - |     | qSanger technology combines spike-in technology with custom-built, proprietary signal processing and applies it to Sanger sequencing and